Market Overview

UPDATE: JP Morgan Raises PT on Pfizer on Takeaways from Meeting with Management

Related PFE
UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease
Fast Money Picks For August 28
Treasury Develolping Options to Curb Inversions (Fox Business)

JP Morgan maintained Pfizer (NYSE: PFE) with an Overweight rating and raised the price target from $31.00 to $32.00.

JP Morgan analyst Chris Schott commented, "Overall, we see several interesting assets in Pfizer's pipeline beyond Eliquis and Xeljanz (most notably PD-991) and believe we are beginning to see results from the company's refocused R&D efforts. In addition, we continue to believe that a larger break-up of Pfizer remains a distinct possibility, particularly if the company's core pharmaceutical portfolio is able to generate sustained growth over time."

Pfizer closed at $27.99 on Tuesday.

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters